Trials / Completed
CompletedNCT00170664
Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- North Eastern German Society of Gynaecological Oncology · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel | |
| DRUG | Carboplatin |
Timeline
- Start date
- 1999-01-01
- Primary completion
- 2003-03-01
- Completion
- 2004-09-01
- First posted
- 2005-09-15
- Last updated
- 2016-03-25
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00170664. Inclusion in this directory is not an endorsement.